The application of these inhibitors might be repurposed for the treatment of pathological vascular outgrowth associated with ocular diseases and cancer, as recent insights into EC metabolism have depicted a pivotal role of GLS1 in angiogenesis [23,24]. The gene discussed is GLS; the disease is cancer.